Leuven (BELGIUM) – March 9, 2010 – TiGenix NV (NYSE EURONEXT: TIG) provides an update on the launch of ChondroCelect and the status of reimbursement applications.
TiGenix has begun the commercial launch of its lead product, ChondroCelect, for the treatment of cartilage damage in the knee, in the initial target markets which include Germany, Belgium, United Kingdom and the Netherlands. The first commercial patients have been treated and initial revenues have been generated. Reimbursement dossiers have also been submitted in the target markets and negotiations on pricing and reimbursement with local health insurance authorities and payers are ongoing and are progressing as planned, with feedback expected in the second half of this year.
